Director at PharmaCyte Biotech (PMCB) gets 119,170 options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
PharmaCyte Biotech, Inc. director Wayne Remell Walker received a grant of stock options covering 119,170 shares of common stock. The options have an exercise price of $0.67 per share and expire on March 30, 2036, with 119,170 derivative securities held after this grant.
According to the filing, the options will vest in full on the date of the company’s next annual meeting of stockholders, subject to Mr. Walker’s continued service. This award is characterized as a grant or other acquisition of derivative securities rather than an open-market purchase.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
WALKER WAYNE REMELL
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 119,170 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 119,170 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Options granted: 119,170 options
Exercise price: $0.67 per share
Underlying shares: 119,170 shares
+2 more
5 metrics
Options granted
119,170 options
Stock Option (Right to Buy) grant to director
Exercise price
$0.67 per share
Conversion or exercise price of stock options
Underlying shares
119,170 shares
Common stock underlying the options
Post-grant derivative holdings
119,170 derivative securities
Total derivative securities following transaction
Option expiration date
March 30, 2036
Expiration date of the stock options
Key Terms
Stock Option (Right to Buy), Grant, award, or other acquisition, derivative securities, vest in full
4 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
derivative securities financial
"derivativeTransactionCount: 1 derivative-type records"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
vest in full financial
"The options shall vest in full on the date of the Issuer's next annual meeting"
FAQ
What did PharmaCyte Biotech (PMCB) director Wayne Remell Walker receive in this Form 4 filing?
Wayne Remell Walker received a grant of stock options covering 119,170 shares of PharmaCyte Biotech common stock. These options are a compensation-related award, not an open-market purchase, and are classified as a grant, award, or other acquisition of derivative securities.
What is the exercise price and expiration date of Wayne Walker’s PharmaCyte (PMCB) stock options?
The granted stock options have an exercise price of $0.67 per share and expire on March 30, 2036. This means Walker can buy PharmaCyte common stock at $0.67 per share any time before the March 30, 2036 expiration, once the options are vested.
When do Wayne Walker’s new PharmaCyte (PMCB) stock options vest?
The options will vest in full on the date of PharmaCyte Biotech’s next annual meeting of stockholders, subject to Wayne Walker’s continued service. Vesting in full means all 119,170 optioned shares become exercisable at that meeting date if he remains in his role.
How many PharmaCyte (PMCB) derivative securities does Wayne Walker hold after this grant?
After this grant, Wayne Walker holds 119,170 derivative securities related to PharmaCyte Biotech. These represent stock options giving him the right to acquire 119,170 shares of common stock at an exercise price of $0.67 per share, subject to vesting and expiration terms.